EA201070025A1 - Производные сульфонилхинолина - Google Patents
Производные сульфонилхинолинаInfo
- Publication number
- EA201070025A1 EA201070025A1 EA201070025A EA201070025A EA201070025A1 EA 201070025 A1 EA201070025 A1 EA 201070025A1 EA 201070025 A EA201070025 A EA 201070025A EA 201070025 A EA201070025 A EA 201070025A EA 201070025 A1 EA201070025 A1 EA 201070025A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mglur1
- formula
- heteroaryl group
- optionally substituted
- substituted phenyl
- Prior art date
Links
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 2
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 abstract 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Изобретение относится к новым лигандам предпочтительных подтипов рецептора mGluR1 и mGluR5, формулы (I), и/или их солям, и/или гидратам, и/или сольватам, способам и промежуточным продуктам для их получения, фармацевтическим композициям, содержащим эти соединения, и их применению в терапии и/или профилактике состояния, для которого требуется модуляция рецепторов mGluR1 и mGluR5. В формуле (I) Аrпредставляет собой необязательно замещенную фенильную или гетероарильную группу; Arпредставляет собой замещенную фенильную или необязательно замещенную гетероарильную группу; R, R, Rи Rнезависимо представляют собой заместитель, выбранный из водорода, галогена, циано, алкила, алкокси, гидрокси, трифторметила, амино, алкиламино, диалкиламино, аминометила, алкиламинометила, диалкиламинометила.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0700417A HU0700417D0 (en) | 2007-06-18 | 2007-06-18 | Sulfonyl-quinoline derivatives |
HU0800376A HUP0800376A2 (en) | 2008-06-12 | 2008-06-12 | Sulfonyl-quinoline derivatives |
PCT/HU2008/000068 WO2008155588A1 (en) | 2007-06-18 | 2008-06-17 | Sulfonyl-quinoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201070025A1 true EA201070025A1 (ru) | 2010-04-30 |
EA016691B1 EA016691B1 (ru) | 2012-06-29 |
Family
ID=89988338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201070025A EA016691B1 (ru) | 2007-06-18 | 2008-06-17 | Производные сульфонилхинолина |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP2167469B1 (ru) |
JP (1) | JP5543917B2 (ru) |
KR (1) | KR101532101B1 (ru) |
CN (1) | CN101730684B (ru) |
AU (1) | AU2008264999B8 (ru) |
BR (1) | BRPI0812816B8 (ru) |
CA (1) | CA2690079C (ru) |
CO (1) | CO6311082A2 (ru) |
CU (1) | CU23822A3 (ru) |
CY (1) | CY1113251T1 (ru) |
DK (1) | DK2167469T3 (ru) |
EA (1) | EA016691B1 (ru) |
EC (1) | ECSP109884A (ru) |
ES (1) | ES2392905T3 (ru) |
GE (1) | GEP20125524B (ru) |
HK (1) | HK1141009A1 (ru) |
HR (1) | HRP20120877T1 (ru) |
IL (1) | IL202463A (ru) |
MX (1) | MX2009013959A (ru) |
MY (1) | MY146992A (ru) |
NI (1) | NI200900217A (ru) |
NZ (1) | NZ581853A (ru) |
PL (1) | PL2167469T3 (ru) |
PT (1) | PT2167469E (ru) |
RS (1) | RS52495B (ru) |
SI (1) | SI2167469T1 (ru) |
TN (1) | TN2009000511A1 (ru) |
WO (1) | WO2008155588A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065710A1 (ru) * | 2012-10-25 | 2014-05-01 | Ivachtchenko Alexandre Vasilievich | (3-арилсульфонилхинолин-8-ил)-диалкил-амины-селективные антагонисты серотониновых 5-нт6 рецепторов, способы их получения и применения |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2751761A1 (en) * | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
CN104010504B (zh) * | 2011-11-03 | 2016-04-06 | 默沙东公司 | 作为mGluR2负变构调节剂的喹啉甲酰胺和喹啉甲腈的衍生物、组合物、及其用途 |
AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
US9932310B2 (en) | 2016-02-08 | 2018-04-03 | City Of Hope | DNA2 inhibitors for cancer treatment |
KR101893515B1 (ko) * | 2017-06-09 | 2018-08-30 | 영남대학교 산학협력단 | 구리 촉매를 이용한 4-하이드록시-3-설파닐쿠마린 유도체 또는 4-하이드록시-3-설파닐퀴놀리논 유도체의 신규 제조방법 및 이로 제조된 유도체 화합물과 이의 용도 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058303A1 (en) * | 1999-03-29 | 2000-10-05 | Neurogen Corporation | 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
UA76726C2 (ru) * | 2000-10-02 | 2006-09-15 | Янссен Фармацевтика Н.В. | Метаботропические антагонисты рецептора глутамата, способ их получения (варианты), фармацевтическая композиция и способ ее получения |
ES2307919T3 (es) * | 2002-03-27 | 2008-12-01 | Glaxo Group Limited | Derivados de quinolina y su uso como ligandos de 5-ht6. |
EP1664018A1 (en) * | 2003-09-02 | 2006-06-07 | Merck & Co., Inc. | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
CA2547518A1 (en) * | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
AU2006327897A1 (en) * | 2005-12-20 | 2007-06-28 | Richter Gedeon Nyrt. | Quinoline derivatives useful in the treatment of mGluR5 receptor-mediated disorders |
-
2008
- 2008-06-17 EA EA201070025A patent/EA016691B1/ru unknown
- 2008-06-17 MX MX2009013959A patent/MX2009013959A/es active IP Right Grant
- 2008-06-17 PT PT08762671T patent/PT2167469E/pt unknown
- 2008-06-17 GE GEAP200811651A patent/GEP20125524B/en unknown
- 2008-06-17 KR KR1020097025394A patent/KR101532101B1/ko active IP Right Grant
- 2008-06-17 AU AU2008264999A patent/AU2008264999B8/en active Active
- 2008-06-17 BR BRPI0812816A patent/BRPI0812816B8/pt active IP Right Grant
- 2008-06-17 MY MYPI20095244A patent/MY146992A/en unknown
- 2008-06-17 EP EP08762671A patent/EP2167469B1/en active Active
- 2008-06-17 WO PCT/HU2008/000068 patent/WO2008155588A1/en active Application Filing
- 2008-06-17 JP JP2010512781A patent/JP5543917B2/ja active Active
- 2008-06-17 SI SI200830764T patent/SI2167469T1/sl unknown
- 2008-06-17 ES ES08762671T patent/ES2392905T3/es active Active
- 2008-06-17 CN CN2008800207550A patent/CN101730684B/zh active Active
- 2008-06-17 CA CA2690079A patent/CA2690079C/en active Active
- 2008-06-17 RS RS20120457A patent/RS52495B/en unknown
- 2008-06-17 NZ NZ581853A patent/NZ581853A/xx unknown
- 2008-06-17 PL PL08762671T patent/PL2167469T3/pl unknown
- 2008-06-17 DK DK08762671.9T patent/DK2167469T3/da active
-
2009
- 2009-12-02 IL IL202463A patent/IL202463A/en active IP Right Grant
- 2009-12-09 TN TNP2009000511A patent/TN2009000511A1/fr unknown
- 2009-12-15 NI NI200900217A patent/NI200900217A/es unknown
- 2009-12-16 CU CU20090219A patent/CU23822A3/es active IP Right Grant
-
2010
- 2010-01-15 CO CO10003762A patent/CO6311082A2/es active IP Right Grant
- 2010-01-18 EC EC2010009884A patent/ECSP109884A/es unknown
- 2010-07-20 HK HK10107003.8A patent/HK1141009A1/xx unknown
-
2012
- 2012-10-25 CY CY20121101007T patent/CY1113251T1/el unknown
- 2012-10-30 HR HRP20120877AT patent/HRP20120877T1/hr unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065710A1 (ru) * | 2012-10-25 | 2014-05-01 | Ivachtchenko Alexandre Vasilievich | (3-арилсульфонилхинолин-8-ил)-диалкил-амины-селективные антагонисты серотониновых 5-нт6 рецепторов, способы их получения и применения |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201070025A1 (ru) | Производные сульфонилхинолина | |
PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
JOP20200338A1 (ar) | عامل وقائي أو علاجي للضمور العضلي نخاعي المنشأ | |
EA200970156A1 (ru) | Пиридизиноновые производные | |
MX2009010909A (es) | Derivados de ftalazino y su uso como medicamento para tratar el cancer. | |
NZ616298A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
EA201170096A1 (ru) | Замещенные производные пиримидона | |
MA33304B1 (fr) | Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
EA200801536A1 (ru) | Новые тиенопирсульфоновые производные | |
MX338631B (es) | 5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
AR060813A1 (es) | Moduladores de mglur5 iii | |
MY162998A (en) | Ethynyl derivatives | |
EA201391537A1 (ru) | ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 | |
MX2014004144A (es) | Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
RS54415B1 (en) | BENZAMIDE SUBSTITUTED DERIVATIVES | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
AR060652A1 (es) | Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii) | |
MY153042A (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | |
PE20081162A1 (es) | Pirazoles sustituidos, composiciones que los contienen, procedimientos de fabricacion y utilizacion | |
RS54248B1 (en) | NEW UNITS AS LISTS OF HISTAMINE H3 RECEPTORS | |
EA200970911A1 (ru) | Хинолины и их терапевтическое применение | |
DK1303512T3 (da) | Fremgangsmåde til fremstilling af arylacetylaminothiazoler |